We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
LabCorp & Interpace Team Up, Drive Specialty Diagnostics
Read MoreHide Full Article
Laboratory Corporation of America Holdings or LabCorp (LH - Free Report) has recently entered into a national agreement with Interpace Diagnostics Group, Inc. (IDXG - Free Report) in the field of cytopathology. On one hand, this win-win alliance will expand Interpace’s nationwide network of cytology providers, supporting its Thyroid molecular business unit. While on the other, it will be helpful in strengthening LabCorp’s core specialty diagnostics arm.
Notably, this is not the first time that LabCorp has partnered with Interpace. In fact, this latest agreement builds upon the original deal inked in 2016. The earlier contract enabled electronic ordering and result reporting via LabCorp for the Interpace’s proprietary ThyGenX and ThyraMIR tests. The reports provided more specific diagnostic information about the presence of thyroid cancer in patients, whose initial biopsy fails to indicate if a thyroid nodule is malignant or benign.
Under the new agreement, Dianon Pathology — a member of the LabCorp Specialty Testing Group — will perform the thyroid biopsy analysis. If the result is indeterminate, then Interpace will perform the molecular tests. This apart, doctors can order an automatic reflex to Interpace’s tests from Dianon in the event of an indefinite biopsy assessment. In either case, Dianon will automatically refer those samples to Interpace to perform the company’s proprietary assays, ThyGenX and ThyraMIR.
It is important to note that LabCorp works hard on new innovations with academic institutions as part of its three key strategic plans to capture the growing lab testing market through advanced assays and tools.
In Diagnostics, the company successfully continues to provide foundation for new collaborations with health systems, large physician groups and managed care partners. It constantly increases its scale and competency levels in clinical laboratory medicine by resorting to acquisitions ranging from routine capabilities to highly esoteric testing.
Among the company’s other recent tie-ups, worth mentioning are its two major health systems partnerships namely Mount Sinai Health System and PAML, a Pacific Northwest-based market-leading reference and outreach laboratory.
Per LabCorp, these anchor health systems will gradually become research hubs, improving access to trials as well as Covance's site activation and investigator and patient recruitment capabilities.
LabCorp has also created ample growth opportunities for women's health with medical drug monitoring, genetics and oncology testing as well as effected critical collaborations such as Walgreens and 23andMe. Also, its partnerships with Mount Sinai and PAML's former owners, Providence and Catholic Health, continue to expand.
Additionally, LabCorp expects the above three transactions to benefit from full-year ownership and growth to generate approximately $500 million in incremental profitable revenues for 2018.
Share Price Performance
Over the past three months, shares of LabCorp have outperformed its industry. The stock has gained 6.1% compared with the industry’s growth of 0.1%.
Zacks Rank & Key Picks
LabCorp carries a Zacks Rank #3 (Hold). Two better-ranked stocks in the broader medical sector are Bio-Rad Laboratories (BIO - Free Report) and PerkinElmer .
PerkinElmer has a long-term expected earnings growth rate of 12.3%. The stock carries a Zacks Rank #2 (Buy).
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
LabCorp & Interpace Team Up, Drive Specialty Diagnostics
Laboratory Corporation of America Holdings or LabCorp (LH - Free Report) has recently entered into a national agreement with Interpace Diagnostics Group, Inc. (IDXG - Free Report) in the field of cytopathology. On one hand, this win-win alliance will expand Interpace’s nationwide network of cytology providers, supporting its Thyroid molecular business unit. While on the other, it will be helpful in strengthening LabCorp’s core specialty diagnostics arm.
Notably, this is not the first time that LabCorp has partnered with Interpace. In fact, this latest agreement builds upon the original deal inked in 2016. The earlier contract enabled electronic ordering and result reporting via LabCorp for the Interpace’s proprietary ThyGenX and ThyraMIR tests. The reports provided more specific diagnostic information about the presence of thyroid cancer in patients, whose initial biopsy fails to indicate if a thyroid nodule is malignant or benign.
Under the new agreement, Dianon Pathology — a member of the LabCorp Specialty Testing Group — will perform the thyroid biopsy analysis. If the result is indeterminate, then Interpace will perform the molecular tests. This apart, doctors can order an automatic reflex to Interpace’s tests from Dianon in the event of an indefinite biopsy assessment. In either case, Dianon will automatically refer those samples to Interpace to perform the company’s proprietary assays, ThyGenX and ThyraMIR.
It is important to note that LabCorp works hard on new innovations with academic institutions as part of its three key strategic plans to capture the growing lab testing market through advanced assays and tools.
In Diagnostics, the company successfully continues to provide foundation for new collaborations with health systems, large physician groups and managed care partners. It constantly increases its scale and competency levels in clinical laboratory medicine by resorting to acquisitions ranging from routine capabilities to highly esoteric testing.
Among the company’s other recent tie-ups, worth mentioning are its two major health systems partnerships namely Mount Sinai Health System and PAML, a Pacific Northwest-based market-leading reference and outreach laboratory.
Per LabCorp, these anchor health systems will gradually become research hubs, improving access to trials as well as Covance's site activation and investigator and patient recruitment capabilities.
LabCorp has also created ample growth opportunities for women's health with medical drug monitoring, genetics and oncology testing as well as effected critical collaborations such as Walgreens and 23andMe. Also, its partnerships with Mount Sinai and PAML's former owners, Providence and Catholic Health, continue to expand.
Additionally, LabCorp expects the above three transactions to benefit from full-year ownership and growth to generate approximately $500 million in incremental profitable revenues for 2018.
Share Price Performance
Over the past three months, shares of LabCorp have outperformed its industry. The stock has gained 6.1% compared with the industry’s growth of 0.1%.
Zacks Rank & Key Picks
LabCorp carries a Zacks Rank #3 (Hold). Two better-ranked stocks in the broader medical sector are Bio-Rad Laboratories (BIO - Free Report) and PerkinElmer .
Bio-Rad Laboratories sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.The company has a long-term expected earnings growth rate of 20%.
PerkinElmer has a long-term expected earnings growth rate of 12.3%. The stock carries a Zacks Rank #2 (Buy).
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>